Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | FPR2 | P25090 | 2/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL739018 | 1.00 | ACE (0.51) | ACENPSR1FPR2ECE1PTPN1 | |
| SCHEMBL8703498 | 0.88 | ACE (0.52) | ACENPSR1FPR2ECE1PTPN1 | |
| SCHEMBL6254380 | 0.88 | PTPN1 (0.56) | ACEPTPN1 | |
| SCHEMBL71782 | 0.83 | ACE (0.56) | ACENPSR1FPR2ECE1L3MBTL1 | |
| SCHEMBL71781 | 0.83 | ACE (0.56) | ACENPSR1FPR2ECE1L3MBTL1 | |
| SCHEMBL933401 | 0.83 | ACE (0.56) | ACENPSR1FPR2ECE1L3MBTL1 | |
| SCHEMBL7322706 | 0.81 | MME (0.59) | ACEMMEACE2CPA1 | |
| SCHEMBL7348036 | 0.81 | MME (0.59) | ACEMMEACE2CPA1 | |
| SCHEMBL9223334 | 0.80 | NPSR1 (0.55) | ACENPSR1L3MBTL1MMEALDH1A1 | |
| SCHEMBL2622217 | 0.80 | NPSR1 (0.55) | ACENPSR1L3MBTL1MMEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192765-A1 | PEPTIDES TARGETING SHP2 AND USES THEREOF | Università Degli Studi di Roma "Tor Vergata" (IT) | 2023-06-22 | — | — | US | claimed |
| EP-4114849-A1 | PEPTIDES TARGETING SHP2 AND USES THEREOF | Universita' degli Studi di Roma " Tor Vergata" (IT) | 2023-01-11 | — | — | EP | claimed |
| WO-2021176072-A1 | PEPTIDES TARGETING SHP2 AND USES THEREOF | Università Degli Studi di Roma "Tor Vergata" (IT) | 2021-09-10 | — | — | WO | claimed |
| US-20060148715-A1 | Structural requirements for STAT3 binding and recruitment to phosphotyrosine ligands | BAYLOR COLLEGE OF MEDICINE (US) | 2006-07-06 | — | — | US | claimed |
| WO-2006069001-A2 | STRUCTURAL REQUIREMENTS FOR STAT3 BINDING AND RECRUITMENT TO PHOSPHOTOTYROSINE LIGANDS | BAYLOR COLLEGE OF MEDICINE (US) | 2006-06-29 | — | — | WO | claimed |
| US-5801149-A | PEPTIDS FOR INHIBITION OF PROTEINS | JOSLIN D-ABETES CENTER, INC. (US) | 1998-09-01 | — | — | US | claimed |
| WO-1994008600-A1 | INHIBITION OF SIGNAL TRANSDUCTION MOLECULES | JOSLIN DIABETES CENTER (US) | 1994-04-28 | — | — | WO | claimed |
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260115301-A1 | INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4717776-A2 | POLYPEPTIDE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | Ohio State Innovation Foundation (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4706689-A2 | COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS | Entrada Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260028630-A1 | HYBRID OLIGONUCLEOTIDES | ENTRADA THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12496350-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | OHIO STATE INNOVATION FOUNDATION (US) | 2025-12-16 | — | — | US | disclosed |
| WO-1996030332-A1 | O-MALONYLTYROSYL COMPOUNDS, O-MALONYLTYROSYL COMPOUND-CONTAINING PEPTIDES, AND USES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTHA ND HUMAN SERVICES (US) | 1996-10-03 | — | — | WO | disclosed |
| WO-1996026961-A2 | PEPTIDYL COMPOUNDS COMPRISING AN ITIM MOTIF WHICH REGULATE HEMATOPOIETIC FUNCTION AND THEIR USE | NATIONAL JEWISH CENTER FOR IMMUNOLOGY AND RESPIRATORY MEDICINE (US) | 1996-09-06 | — | — | WO | disclosed |
| WO-1995034201-A1 | pp60PIK: A DOWNSTREAM ELEMENT IN INSULIN SIGNALING | JOSLIN DIABETES CENTER, INC. (US) | 1995-12-21 | — | — | WO | disclosed |
| US-5475129-A | Phosphonoalkyl phenylalanine compounds suitably protected for use in peptide synthesis | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1994008600-A1 | INHIBITION OF SIGNAL TRANSDUCTION MOLECULES | JOSLIN DIABETES CENTER (US) | 1994-04-28 | — | — | WO | disclosed |
| WO-1993025561-A1 | PHOSPHONOALKYL PHENYLALANINE COMPOUNDS SUITABLY PROTECTED FOR USE IN PEPTIDE SYNTHESIS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-12-23 | — | — | WO | disclosed |
| US-5264607-A | Process of making benzylic α,α-diflurophosphonates from benzylic α-ketophosphorates | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115301-A1 | INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | SLC7A1, SRM, SLC6A19 | ACE 4318/4885NPSR1 1435/4885FPR2 618/4885 |
| US-20260028630-A1 | HYBRID OLIGONUCLEOTIDES | RNGTT, BCDIN3D, RNMT | ACE 3520/4885NPSR1 2377/4885FPR2 2989/4885 |
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, SLC7A1, SLC6A15 | ACE 1946/4885NPSR1 3759/4885FPR2 570/4885 |
| US-20060148715-A1 | Structural requirements for STAT3 binding and recruitment to phosphotyrosine ligands | STAT3, JAK2, STAT5B | ACE 4033/4885NPSR1 2608/4885FPR2 3373/4885 |
| US-12496350-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | CNBP, CALU, CLSPN | ACE 1416/4885NPSR1 1332/4885FPR2 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.